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Objective: Coronary artery disease(CAD)  patients living in Elazığ region is to assess the levels of 
matrix metalloproteinase-9(MMP-9) and myeloperoxidase(MPO), polymorphisms MPO gene. 
 
Research Design and Methods: Eighty-eight patients with angiographically diagnosed coronary artery 
disease between the ages of 18-80 who applied to Department of Cardiology, Faculty of Medicine, 
Firat University were enrolled in this study. MPO, MMP-9 levels in plasma samples of individuals 
were determined by enzyme-linked immuno sorbent assay (ELISA) according to the kit procedure. 
MPO polymorphism was studied using the PCR-RFLP technique. 
 
Results: When plasma MPO and MMP-9 levels were compared in the control and CAD groups; MPO 
levels were statistically significant (p <0.05). MMP-9 levels were not statistically significant. MPO 
gene polymorphism was not found statistically significant in CAD. 
 
Conclusion: MPO gene polymorphism is thought to be associated with greater population populations 
in CAD and may be used in the future as a biomarker for plasma MPO enzyme levels in CAD. 
 





Oxidative stress plays an important role in the initiation and progression of cardiovascular disease (1). 
Oxidative stress biomarkers have been identified in coronary artery disease (CAD) (2-4).  CAD has a 
multifactorial etiology, and it is thought to result from an interaction between genetic background and 
environmental factors (5-7).  
Myeloperoxidase (MPO) is a potent oxidative enzyme and it is expressed by neutrophils, monocytes, 
and some populations of macrophages. It catalyzes the modification of LDL in atherogenesis (8). MPO 
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has an important role in infectious diseases and in CAD (9). Several studies have shown that there is an 
association between MPO levels and CAD (8). Levels of MPO activity is associated with various 
genetic polymorphisms so that associated with cardiovascular risk (10). It has been shown that elevated 
MPO levels are associated with coronary artery disease (CAD) (11).  
The gene coding for human myeloperoxidase, is located in chromosome 17q23.1. A few 
polymorphisms are described for the MPO gene that affects its transcription (12). In this 
polymorphism, the presence of a G rather than A at position 463 bp gives rise to three different 
genotypes: AA, AG and GG. To date, a number of studies have been suggested the potential 
association between the MPO G-463A polymorphism and CAD. However the results were inconsistent. 
Some of this studies have shown that GG genotype is a significant predictor of CAD and endothelial 
dysfunction when compared to AA/AG genotypes (13-16).  
Nikpoor et all., showed that individuals with A allele has a lower activity of the MPO and so that it 
leads to lower oxidation of LDL, therefore A allele of the MPO genotype has a protective role in the 
occurrence of CAD (13). Nevertheless, there are conflicting data on the relation between MPO levels 
and its polymorphism with CAD (17,18).  
Matrix metalloproteinases (MMPs) are a family of zinc-containing endoproteinases which mainly 
secreted by monocyte-derived macrophage and vascular smooth muscle cells (19). MMP-9 is the most 
studied enzyme in the MMP-family. It is a key enzyme which determinant of extracellular matrix 
degradation, and collagen is the main substrate of MMP-9. MMP-9 concentrations and activity was 
higher in human atherosclerotic plaques (20–23).  The serum level of MMP-9 might be a sensitive 
inflammation marker (24) and a predictor of cardiovascular mortality in patient with CAD (25). 
The purpose of this study was to test the hypothesis that MPO polymorphism −463A/G is associated 
with CAD. In addition, as secondary objective we also investigated the association between CAD and 
MPO, MMP-9 plasma levels. Oxidative stress parameters have been evaluated in CAD frequently. 
However, there has not been much published work related to oxidative stress in CAD patients in 
Turkey. Similarly, not much literature is available on myeporexoidase and MMP-9 level; MPO gene 
polymorphism and its association with lipids in CAD patients in Turkey. We, therefore evaluated these 
parameters in CAD patients. 
  
Materials and Methods 
The patient population and documentation of CAD severity 
This was a case–control study. The cases and controls were the angiographically confirmed.    The 
study sample comprised 176 persons who underwent coronary angiography for diagnostic purposes.  
The angiograms were assessed by two cardiologists who were unaware that the patients were to be 
included in the study. The three main arteries (left anterior descending artery, left circumflex artery, or 
right coronary artery) were classified as free of disease, or presenting ≥50 % stenosis. Patients having a 
normal angiogram with no atherosclerosis or lesions in coronary arteries were considered as CAD 
control subjects (n = 88). (Table 1).  Written informed consent was obtained from all subjects, and a 
local ethical committee approved the study protocol. 
 
Blood sample collection 
Patients were fasted for at least 6 h before venous blood samples were drawn into 5 mL EDTA vacuum 
tubes and blood samples were separated in a refrigerated centrifuge within 15 min of collection for 
determination of plasma MPO and MMP-9. Plasma was divided into small aliquots, stored at –20oC 
until analysis. For determination of serum lipids, a blood sample was obtained from the cubital vein of 
each participant and the samples were sent for detection within 1 h. by using the Advia 1800 (Siemens 
Diagnostics, Tarrytown, NY, USA) autoanalyzer and reactives. 
 
Determination of plasma levels of MPO and MMP-9  
Plasma levels of MPO (Boster Bıologıcal Technology Co.,Ltd.  USA; Cat no: EK0850) and MMP-9 
(Boster Bıologıcal Technology Co.,Ltd.  USA; Cat no: EK0465) were measured by enzyme-linked 
immunosorbent assay according to kit protocols.    
 
Genotyping 
DNA was extracted from EDTA anti-coagulated whole blood from all subjects (controls and patients) 
and was prepared from DNA isolation kit (Sigma-Aldrich, GenElute Blood genomic DNA Kit, Catalog 
no: NA2010, Germany). The MPO 463 -A/G polymorphism was genotyped by restriction fragment 
length polymorphism (RFLP) assay. The polymorphic site at position -463 of the MPO gene was 
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amplified with use of forward primer (50-CGG TAT AGG CAC ACA ATG GTG AG-30) and reverse 
primer (50-GCA ATG GTT CAA GCG ATT CTT C-30) as described in the literature. 
Amplification was carried out in a volume of 20 μl containing 1 - 10μg of genomic DNA, 10 pmol of 
each primer, 0.5 mM of each dNTP, reaction buffer, and 1.0 U of Taq DNA polymerase. Amplified 
products were digested overnight with Aci I at 37 oC. The resulting fragments were 289 bp for A/A, 
289, 169, 120 bp for A/G and allele and 169, 120 bp for GG genotype. 
 
Statistical analysis 
All of the statistical analyses were performed by using the SPSS 12.0 statistical package. We have 
presented normally distributed data as mean ± S.D. Categorical variables are presented by frequency of 
counts, and inter group comparisons analysed by a chi-squared analysis. We compared cases and 
controls on biochemical parameters and MPO levels using Student’s t-test. Anova test was used to 
investigate the plasma lipid, MPO and MMP-9 levels between the genotypes. When we analyzed the 
quantitative relationships between MPO and MMP-9, bivariate 
correlation coefficients were calculated, using Pearson’s for parametric data. For the comparisons of 
the values of different groups, P< 0.05 was considered statistically significant.  
 
Results 
Clinical characteristics of patients with and controls: 
The clinical characteristics of the patients and controls are shown in Table 1. Total cholesterol and 
LDL cholesterol levels were significantly higher in patients (p<0.0001 and p<0.01 respectively). Levels 
of triglyceride and HDL cholesterol were not significantly different among groups. Sistolic blood 
pressure and the fregquency of smoking were higher in patients (p<0.05, p<0.01, respectively). MPO 
level was higher in CAD patients (p<0.05) although MMP-9 level was not significantly different 
among groups (figure 1). 
 
Figure 1. Plasma MPO and MMP-9 levels in control and CAD patients. 
 
Table 1. Clinical characteristics of individuals with CAD and controls 
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Genotypic and allelic frequencies for the study groups are shown in Table 2. No statistically significant 
difference found in the distribution of the MPO -463 G/A genotye and allele fequency in the patients 
and control groups. 
 









Genotype     
GG Genotype  63 (% 71,6)  64 (% 72,7) 
AG Genotype  23 (% 26,1)  21 (% 23,9) 
AA Genotype  2 (%2,3)  3 (% 3,4) 
Allele     
G Allele  %84,66  %84,66 
A Allele  %15,34  %15,34 
 
 
Association of the MPO gene polymorphism with lipids, MPO and MMP-9 levels. 
Table 3 shows the association between the MPO gene polymorphism and lipid levels, Figure 2 shows 
the association between the MPO gene polymorphism and MPO, MMP-9 levels in controls and patiens 
with CAD, respectively. The higher total cholesterol, LDL-cholesterol and HDL cholesterol level was 
shown in the AA genotype in controls and patients but this was not statistically significant. No 
statistically significant difference found in the levels of MPO and MMP-9 among genotypes of MPO in 
controls and patients with CAD.  
 




Figure 2. MPO and MMP-9 levels of the study subjects according to MPO genotypes in controls and 
patients. 
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in this study we found that in healthy groups with G allele had elevated MPO levels than A allele 
(p<0.05) and among subjects with G alleles, CAD patients with G allele had higher level of MPO 
compared with controls (p<0.005) (Figure 3).  
 
 
Figure 3. MPO levels in CAD patients and control subjects according to MPO alleles. 
 
 
Correlations between MPO and MMP-9 in total population 
Figure 4 shows the correlaitons between MPO and MMP-9 level in total population. There was a 
significant positive correlation between MPO and MMP-9 level (r = 0.243, P = 0.01). 
 
 
Figure 4. Correlations between MPO and MMP-9 in total population 
 
Discussion 
In this study we assessed plasma levels of MPO, MMP-9 and MPO gene polymorphism in CAD 
patients and control subjects in whom the presence of CAD was defined by coronary angiographic 
examination. The main findings of this study are as follows: (i) In patients with angiographically 
proven CAD, plasma MPO levels are elevated as compared with subjects without CAD; (ii) In patients 
with angiographically proven CAD, plasma MMP-9 levels are not difference as compared with subjects 
without CAD; (iii) We did not observed any significant differences between MPO genotypes and study 
groups and (iv) A positive correlation between MPO and MMP-9 level was found.  
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CAD remains a heterogeneous disease with a wide range of clinical presentations and outcomes. 
Various systemic markers of inflammation have been investigated associated with CAD and 
cardiovascular events (26). The importance of PMN degranulation of MPO in the coronary circulation 
have emerged as powerful predictors of adverse outcome in patients with CAD (27-29). MPO is a 
redox-active hemoprotein released by activated neutrophils and is associated with inflammation and 
oxidative stress. Its role in catalyzing the formation of oxidizing agents. Hypochlorous acid, tyrosyl 
radical, and nitrogen dioxide are the products of MPO and they can contribute to oxidative damage of 
host lipids and proteins, leading to atherosclerosis.   Brennan and colleagues (28) assessed the 
predictive value of serum MPO levels in patients with chest pain at a hospital emergency department. 
Serum MPO levels were significantly higher in patients who subsequently had a myocardial infarction 
(MI) within 16 hours of presentation (28).  In a case-control study of 158 patients with CAD and 175 
controls, Zhang et al. (11) have shown that elevated levels of blood MPO were associated with the 
presence of CAD. In the present study, we showed that corroborates the findings by Zhang et al. (11) in 
a series of patients in Turkey.   
A few polymorphisms are described for the MPO gene, including the −638C/A, the V53F and the 
−463A/G (30). These polymorphisms could be genetically asociated with the pathophysiology of 
cardiovascular diseases. We chose the −463A/G due to continuous literatures associated with coronary 
artery disease (13-16). Some studies have shown that GG genotype is associated with increased 
incidence of CAD (13-16), however, others failed to demonstrate a relation between MPO 
polymorphisms and atherosclerosis. We did not observed any significant differences between MPO 
genotypes and study groups. Furhermore, according to MPO -463 G/A allele in healthy groups with G 
allele had elevated MPO levels than A allele (p<0.05) and subjects with G alleles, CAD patients with G 
genotype had higher level of MPO compared with controls (p<0.005).  
Our study and the results have present certain limitations, since the study-group was obtained from a 
single hospital in East of Turkey, and the samples might not include all the characteristics of patients 
from other centers. It is also accepted that CAD is a disease effected by multiple genes and 
environmental factors. Furthermore, since the MPO AA genotype is relatively infrequent, the actual 
value of genotype detection in the primary prevention of CAD may be disputable. However, to date, a 
number of studies  have been conducted to assess the potential association between the MPO G-463A 
polymorphism and CAD. However the results were inconsistent. 
MMPs had been identified in vascular remodeling process. They play an important role in the 
pathogenesis and progression of atherosclerosis (31). Several studies have shown the importance of 
these enzymes in development and progression of heart failure (32-34).  
Some cross-sectional studies have reported that the plasma MMP-9 level was significantly higher in 
CAD patients (35,36). Blankenberg et al. (2003) showed that plasma MMP-9 concentration was higher 
in patients with CAD and might be a novel predictor of cardiovascular disease (25). In the present 
study, we investigated the association of the MMP-9 levels with coronary artery disease. We did not 
observed any significant differences in MMP-9 levels between controls and CAD patients. However, 
some other cohort studies suggested that serum MMP-9 is not a strong predictor of CAD (37,38). These 
inconsistent results can be explained as; plasma MMP-9 level is affected by many factors, such as 
genetic polymorphisms of MMP-9, drugs, and other factors. Lacchini et al. (2010) found that there are 
interethnic differences in MMP-9 genetic polymorphisms (39). furthermore, in our study, MPO levels 
were correlated with the increase in MMP-9 concentration (P = 0.01), supporting the previous 
mentioned hypothesis, that neutrophils could be the major contributors for increased MMP-9 levels. 
 
Conclusions 
Observations from this study suggest that MPO level was significantly higher in CAD patients but 
there was no significant association between MMP-9 level and CAD. We found that there was no 
significant differences between MPO genotypes and study groups. It is also generally accepted that 
CAD is a disease produced by both multiple genes and environmental factors, and many other genes 
could be potential candidates for CAD. Our results have present certain limitations, since the study-
group was obtained from a single hospital in east of Turkey, and the samples might not include all the 
characteristics of patients from other centers. However, further studies may be carried out in a larger 
population. 
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